Richard Bartram - Oct 29, 2021 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
Chief Financial Officer
Signature
/s/ Richard B. Bartram
Stock symbol
ESPR
Transactions as of
Oct 29, 2021
Transactions value $
$0
Form type
4
Date filed
11/1/2021, 04:48 PM
Previous filing
Jun 30, 2021
Next filing
Mar 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award $0 +18.7K +74.35% $0.00 43.9K Oct 29, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ESPR Stock Option (right to buy) 26.5K Oct 29, 2021 Common Stock 26.5K $8.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The awards will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label.
F2 Consists of 43,852 shares of common stock held, including 1,535 shares acquired in Esperion's Employee Stock Purchase Plan.